Patients with PWS and related syndromes display differentially methylated regions involved in neurodevelopmental and nutritional trajectory.
Genome-wide methylation analysis
MAGEL2
Neurodevelopmental disorder
Prader–Willi
SNORD116
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
13 08 2021
13 08 2021
Historique:
received:
17
02
2021
accepted:
29
07
2021
entrez:
14
8
2021
pubmed:
15
8
2021
medline:
10
2
2022
Statut:
epublish
Résumé
Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by a paternal deficiency of maternally imprinted gene expression located in the chromosome 15q11-q13 region. Previous studies have demonstrated that several classes of neurodevelopmental disorders can be attributed to either over- or under-expression of specific genes that may lead to impairments in neuronal generation, differentiation, maturation and growth. Epigenetic changes that modify gene expression have been highlighted in these disorders. One recent study focused on epigenetic analysis and compared patients with PWS with patients with other imprinting disorders. No study, however, has yet focused on epigenetics in patients with PWS specifically by comparing the mutations associated with this syndrome. This study investigated the epigenetic modifications in patients with PWS and patients with PWS-related disorders caused by inactivation of two genes of the PWS chromosomal region, SNORD116 and MAGEL2. Our approach also aimed to compare the epigenetic modifications in PWS and PWS-related disorders. We compared genome-wide methylation analysis (GWAS) in seven blood samples from patients with PWS phenotype (five with deletions of the PWS locus, one with a microdeletion of SNORD116 and one with a frameshift mutation of MAGEL2 presenting with Schaaf-Yang syndrome), as well as two control patients. Controls were infants that had been studied for suspicion of genetic diseases that was not confirmed by the genetic analysis and the clinical follow-up. The analysis identified 29,234 differentially methylated cytosines, corresponding to 5,308 differentially methylated regions (DMRs), which matched with 2,280 genes. The DMRs in patients with PWS were associated with neurodevelopmental pathways, endocrine dysfunction and social and addictive processes consistent with the key features of the PWS phenotype. In addition, the separate analysis for the SNORD116 and MAGEL2 deletions revealed that the DMRs associated with the SNORD116 microdeletion were found in genes implicated in metabolic pathways and nervous system development, whereas MAGEL2 mutations mostly concerned genes involved in macromolecule biosynthesis. The PWS is associated with epigenetic modifications with differences in SNORD116 and MAGEL2 mutations, which seem to be relevant to the different associated phenotypes.
Sections du résumé
BACKGROUND
Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by a paternal deficiency of maternally imprinted gene expression located in the chromosome 15q11-q13 region. Previous studies have demonstrated that several classes of neurodevelopmental disorders can be attributed to either over- or under-expression of specific genes that may lead to impairments in neuronal generation, differentiation, maturation and growth. Epigenetic changes that modify gene expression have been highlighted in these disorders. One recent study focused on epigenetic analysis and compared patients with PWS with patients with other imprinting disorders. No study, however, has yet focused on epigenetics in patients with PWS specifically by comparing the mutations associated with this syndrome.
OBJECTIVE
This study investigated the epigenetic modifications in patients with PWS and patients with PWS-related disorders caused by inactivation of two genes of the PWS chromosomal region, SNORD116 and MAGEL2. Our approach also aimed to compare the epigenetic modifications in PWS and PWS-related disorders.
METHODS
We compared genome-wide methylation analysis (GWAS) in seven blood samples from patients with PWS phenotype (five with deletions of the PWS locus, one with a microdeletion of SNORD116 and one with a frameshift mutation of MAGEL2 presenting with Schaaf-Yang syndrome), as well as two control patients. Controls were infants that had been studied for suspicion of genetic diseases that was not confirmed by the genetic analysis and the clinical follow-up.
RESULTS
The analysis identified 29,234 differentially methylated cytosines, corresponding to 5,308 differentially methylated regions (DMRs), which matched with 2,280 genes. The DMRs in patients with PWS were associated with neurodevelopmental pathways, endocrine dysfunction and social and addictive processes consistent with the key features of the PWS phenotype. In addition, the separate analysis for the SNORD116 and MAGEL2 deletions revealed that the DMRs associated with the SNORD116 microdeletion were found in genes implicated in metabolic pathways and nervous system development, whereas MAGEL2 mutations mostly concerned genes involved in macromolecule biosynthesis.
CONCLUSION
The PWS is associated with epigenetic modifications with differences in SNORD116 and MAGEL2 mutations, which seem to be relevant to the different associated phenotypes.
Identifiants
pubmed: 34389046
doi: 10.1186/s13148-021-01143-0
pii: 10.1186/s13148-021-01143-0
pmc: PMC8361855
doi:
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
159Informations de copyright
© 2021. The Author(s).
Références
Orphanet J Rare Dis. 2016 May 04;11(1):56
pubmed: 27146407
Nat Biotechnol. 2008 Nov;26(11):1293-300
pubmed: 18978777
J Clin Endocrinol Metab. 2011 Jan;96(1):E173-80
pubmed: 20980432
Nature. 2011 Jan 27;469(7331):534-8
pubmed: 21270893
Psychiatr Genet. 2005 Dec;15(4):243-54
pubmed: 16314754
Neuropharmacology. 2013 May;68:2-82
pubmed: 23246909
J Cereb Blood Flow Metab. 2011 Jan;31(1):275-82
pubmed: 20588317
Trends Endocrinol Metab. 2018 Jun;29(6):361-363
pubmed: 29454745
Am J Med Genet A. 2014 Sep;164A(9):2180-6
pubmed: 24850752
Genomics. 2012 Jan;99(1):10-7
pubmed: 22044633
Bioinformatics. 2014 Sep 1;30(17):2414-22
pubmed: 24836530
Dialogues Clin Neurosci. 2017 Jun;19(2):193-201
pubmed: 28867943
Am J Med Genet A. 2004 Jan 15;124A(2):158-64
pubmed: 14699614
Cell Rep. 2018 Mar 27;22(13):3401-3408
pubmed: 29590610
Nucleic Acids Res. 2019 Jan 8;47(D1):D559-D563
pubmed: 30357367
Pediatrics. 2017 Feb;139(2):
pubmed: 28100688
Cell Metab. 2009 Jun;9(6):548-55
pubmed: 19490909
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
BMC Pediatr. 2016 Feb 18;16:28
pubmed: 26888082
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
J Clin Endocrinol Metab. 2010 Dec;95(12):E464-7
pubmed: 20810574
Diseases. 2016 Jan 13;4(1):
pubmed: 28933382
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D108-10
pubmed: 16381825
Eur J Hum Genet. 2015 Feb;23(2):252-5
pubmed: 24916642
J Med Genet. 1991 Aug;28(8):511-4
pubmed: 1681108
Am J Med Genet A. 2016 Mar;170(3):594-601
pubmed: 26615966
Front Horm Res. 2014;42:93-106
pubmed: 24732928
PLoS One. 2013 Aug 16;8(8):e72042
pubmed: 23977200
Clin Epigenetics. 2020 Oct 22;12(1):159
pubmed: 33092629
Hum Mutat. 2013 Apr;34(4):595-602
pubmed: 23335487
Obesity (Silver Spring). 2006 Oct;14(10):1685-90
pubmed: 17062796
J Clin Endocrinol Metab. 2008 Nov;93(11):4183-97
pubmed: 18697869
Hum Mol Genet. 2010 Dec 15;19(24):4895-905
pubmed: 20876615
Neurosci Biobehav Rev. 2017 Jan;72:153-167
pubmed: 27836461
Nucleic Acids Res. 2018 Jan 4;46(D1):D296-D302
pubmed: 29126174
Nucleic Acids Res. 2019 Jan 8;47(D1):D1018-D1027
pubmed: 30476213
J Clin Endocrinol Metab. 2008 Jul;93(7):2800-5
pubmed: 18460565
Neuropeptides. 2017 Feb;61:87-93
pubmed: 27823858
Nat Genet. 2004 Aug;36(8):818-26
pubmed: 15273686
Neurobiol Dis. 2019 Jan;121:58-64
pubmed: 30240706
Transl Psychiatry. 2020 Aug 8;10(1):274
pubmed: 32772048
Nat Genet. 2018 Feb;50(2):175-179
pubmed: 29311637
J Pediatr. 2003 Feb;142(2):174-8
pubmed: 12584540
Int J Mol Sci. 2017 Feb 28;18(3):
pubmed: 28264487
Nat Genet. 2018 Feb;50(2):180-185
pubmed: 29311635
Eur J Pediatr. 2016 Jan;175(1):9-18
pubmed: 26584571
J Clin Endocrinol Metab. 2010 Jul;95(7):3532-6
pubmed: 20427492
Sci China Life Sci. 2017 Jul;60(7):692-699
pubmed: 28624953
Pediatrics. 2004 Mar;113(3 Pt 1):565-73
pubmed: 14993551
J Clin Endocrinol Metab. 1995 Feb;80(2):573-9
pubmed: 7852523
Nucleic Acids Res. 2018 Jan 4;46(D1):D649-D655
pubmed: 29145629
J Clin Endocrinol Metab. 2008 May;93(5):1649-54
pubmed: 18303077
Bioinformatics. 2011 Jun 1;27(11):1571-2
pubmed: 21493656
Nucleic Acids Res. 2018 Jan 4;46(D1):D661-D667
pubmed: 29136241
Am J Med Genet A. 2018 Jun;176(6):1369-1374
pubmed: 29696788
Mol Psychiatry. 2021 Jan;26(1):51-59
pubmed: 33082508
Nat Rev Genet. 2011 Jul 18;12(8):565-75
pubmed: 21765458
Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18729-34
pubmed: 20937895
Orphanet J Rare Dis. 2011 Jun 24;6:47
pubmed: 21702900
PLoS One. 2014 Sep 16;9(9):e107320
pubmed: 25226172
PLoS One. 2013 Apr 18;8(4):e61740
pubmed: 23637896